Document is current

Article History

Received: 11 September 2025

Accepted: 19 January 2026

First Online: 21 February 2026

Change Date: 28 April 2026

Change Type: Update

Change Details: This article was originally published under the subscription model but it is now published under an Open Access license.

Declarations

:

: All reported investigations were conducted in accordance with the Declaration of Helsinki and with national regulations. This retrospective analysis was approved by the local Ethics Committee (permit 99/19) and the requirement to obtain informed consent was waived. The administration of 18 F-flotufolastat complied with The German Medicinal Products Act, AMG §13 2b, and the responsible regulatory body (Government of Oberbayern).

: The requirement to obtain informed consent was waived for this study.

: The authors confirm that human research participants provided informed consent for publication of the images in Figs.  and .

: IR, WAW, and ME report fees from Blue Earth Diagnostics Ltd (consultant, research funding). Further, ME reports fees from Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker), and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review), and Bioclinica (image review) outside the submitted work, and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of 18 F-flotufolastat (POSLUMA). WAW reports fees as a consultant and research funding from ITM, Novartis/AAA, Nuclidium, Pentixapharm, Ratio Therapeutics, and RayzeBio (outside the submitted work). WAW is an editor in the European Journal of Nuclear Medicine and Molecular Imaging.